Blog

Jul 10, 2024, 02:42

Charlotte Davison: Myricx Bio has joined the British Patient Capital portfolio

Charlotte Davison, Board Observer at

“Absolutely thrilled to share that Myricx Bio has joined the British Patient Capital portfolio. We are delighted to have participated in this £90m Series A funding to accelerate development of their novel NMTi ADC platform towards clinic.

It’s been a pleaseure to work with Novo Holdings, Abingworth, Eli Lilly and Company, Sofinnova Partners and Brandon Capital along with a stellar team (Robin Carr, Julie Mead, Francesca Zammarchi) to pull this round together.

Congratulations all! ”

Read further.
Source: Charlotte Davison/LinkedIn

Abingworth Brandon Capital British Patient Capital cancer Charlotte Davison Eli Lilly Francesca Zammarchi Julie Mead Myricx Bio Novo Holdings OncoDaily Oncology Robin Carr Sofinnova Partners

FDA Priority Review Granted for TAR-200 After 82% Complete Response in BCG-Unresponsive Bladder Cancer

Paolo Tarantino: AACR Journals' Power Move for Reviewers

Best Immunotherapy Highlights from ESMO TAT ASIA 2025 You Shouldn't Miss

Oncologist Near Me – Nagashree Seetharamu: A Journey of Healing, Mentorship, and Leadership

Mohit Manrao: FDA Grants Priority Review for sBLA in Resectable Early-Stage Gastric and GEJ Cancers